Literature DB >> 11226285

Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells.

B H Park1, B Vogelstein, K W Kinzler.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that have been implicated in a variety of biologic processes. The PPARdelta isotype was recently proposed as a downstream target of the adenomatous polyposis coli (APC)/beta-catenin pathway in colorectal carcinogenesis. To evaluate its role in tumorigenesis, a PPARdelta null cell line was created by targeted homologous recombination. When inoculated as xenografts in nude mice, PPARdelta -/- cells exhibited a decreased ability to form tumors compared with PPARdelta +/- and wild-type controls. These data suggest that suppression of PPARdelta expression contributes to the growth-inhibitory effects of the APC tumor suppressor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226285      PMCID: PMC30184          DOI: 10.1073/pnas.051630998

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Surfing the p53 network.

Authors:  B Vogelstein; D Lane; A J Levine
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

2.  Frequent activation of the beta-catenin-Tcf signaling pathway in nonfamilial colorectal carcinomas with microsatellite instability.

Authors:  K Shitoh; T Furukawa; M Kojima; F Konishi; M Miyaki; T Tsukamoto; H Nagai
Journal:  Genes Chromosomes Cancer       Date:  2001-01       Impact factor: 5.006

3.  Manipulation of transgenes by site-specific recombination: use of Cre recombinase.

Authors:  B Sauer
Journal:  Methods Enzymol       Date:  1993       Impact factor: 1.600

4.  PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.

Authors:  T C He; T A Chan; B Vogelstein; K W Kinzler
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

Review 5.  Peroxisome proliferator-activated receptors: insight into multiple cellular functions.

Authors:  P Escher; W Wahli
Journal:  Mutat Res       Date:  2000-03-17       Impact factor: 2.433

6.  Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer.

Authors:  R A Gupta; J Tan; W F Krause; M W Geraci; T M Willson; S K Dey; R N DuBois
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

7.  Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta).

Authors:  J M Peters; S S Lee; W Li; J M Ward; O Gavrilova; C Everett; M L Reitman; L D Hudson; F J Gonzalez
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

8.  Differential activation of peroxisome proliferator-activated receptors by eicosanoids.

Authors:  K Yu; W Bayona; C B Kallen; H P Harding; C P Ravera; G McMahon; M Brown; M A Lazar
Journal:  J Biol Chem       Date:  1995-10-13       Impact factor: 5.157

9.  Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein.

Authors:  S Munemitsu; I Albert; B Souza; B Rubinfeld; P Polakis
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

10.  Altered growth of human colon cancer cell lines disrupted at activated Ki-ras.

Authors:  S Shirasawa; M Furuse; N Yokoyama; T Sasazuki
Journal:  Science       Date:  1993-04-02       Impact factor: 47.728

View more
  84 in total

1.  National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms.

Authors:  Daniel H Hwang; Victor Fung; Andrew J Dannenberg
Journal:  Neoplasia       Date:  2002 Mar-Apr       Impact factor: 5.715

2.  Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses.

Authors:  Manu Kohli; Carlo Rago; Christoph Lengauer; Kenneth W Kinzler; Bert Vogelstein
Journal:  Nucleic Acids Res       Date:  2004-01-02       Impact factor: 16.971

Review 3.  Crosstalk of oncogenic and prostanoid signaling pathways.

Authors:  Rolf Müller
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-15       Impact factor: 4.553

4.  Stem cell antigen-1 deficiency enhances the chemopreventive effect of peroxisome proliferator-activated receptorγ activation.

Authors:  Hongyan Yuan; Geeta Upadhyay; Yuzhi Yin; Levy Kopelovich; Robert I Glazer
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-28

5.  p8 is critical for tumour development induced by rasV12 mutated protein and E1A oncogene.

Authors:  Sophie Vasseur; Albrecht Hoffmeister; Stephane Garcia; Claude Bagnis; Jean-Charles Dagorn; Juan Lucio Iovanna
Journal:  EMBO Rep       Date:  2002-01-29       Impact factor: 8.807

6.  The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer.

Authors:  Olga Kovbasnjuk; Rakhilya Mourtazina; Boris Baibakov; Thomas Wang; Christian Elowsky; Michael A Choti; Anne Kane; Mark Donowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

Review 7.  The role of peroxisome proliferator-activated receptor gamma in diabetes and obesity.

Authors:  Francesco S Celi; Alan R Shuldiner
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

Review 8.  Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis.

Authors:  O C Trifan; T Hla
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

9.  Chemopreventive n-3 fatty acids activate RXRalpha in colonocytes.

Authors:  Yang-Yi Fan; Thomas E Spencer; Naisyin Wang; Mary P Moyer; Robert S Chapkin
Journal:  Carcinogenesis       Date:  2003-07-04       Impact factor: 4.944

10.  PPARdelta is a fatty acid sensor that enhances mitochondrial oxidation in insulin-secreting cells and protects against fatty acid-induced dysfunction.

Authors:  Kim Ravnskjaer; Francesca Frigerio; Michael Boergesen; Tina Nielsen; Pierre Maechler; Susanne Mandrup
Journal:  J Lipid Res       Date:  2009-11-30       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.